RSNA 2008 

Abstract Archives of the RSNA, 2008


SSJ25-02

Prostate Radiotherapy: Is One or Two Gold Seeds Equivalent to Three?

Scientific Papers

Presented on December 2, 2008
Presented as part of SSJ25: Radiation Oncology and Radiobiology (Genitourinary Malignancies)

Participants

Daryl Lim Joon, Presenter: Nothing to Disclose
Vincent Khoo MD, Abstract Co-Author: Nothing to Disclose
Angelina Mercuri, Abstract Co-Author: Nothing to Disclose
Aldo Rolfo, Abstract Co-Author: Nothing to Disclose
Kenneth Wan, Abstract Co-Author: Nothing to Disclose
Sarah Gonzales, Abstract Co-Author: Nothing to Disclose
Rebecca Stewart, Abstract Co-Author: Nothing to Disclose
Laura Spiteri, Abstract Co-Author: Nothing to Disclose
Monica Handley, Abstract Co-Author: Nothing to Disclose
Margaret Benci, Abstract Co-Author: Nothing to Disclose
Karen Daly, Abstract Co-Author: Nothing to Disclose
Chris Hamilton, Abstract Co-Author: Nothing to Disclose
et al, Abstract Co-Author: Nothing to Disclose

PURPOSE

Gold seed implantation into the prostate is a technique used to localise the prostate during RT, as pelvic bony anatomy does not account for internal prostate motion. The optimal number of seeds for prostate verification has not yet been defined. Many centres including Austin Health use 3 seeds for verification.The main aim of this study was to assess and compare 1 and 2 seed verification to the standard 3 seed match in the prostate targeting process. The secondary endpoint was to compare various seed combinations to traditional bony verification.

METHOD AND MATERIALS

Ten patients with locally advanced prostate cancer were entered into a gold seed verification study. The average age was 71 years, with average PSA and median Gleason scores of 10µg/L and 8 respectively, and T stages from T2a to T3b. Three gold seeds were inserted trans-rectally into the prostate; 1 into the right base, 1 into the left mid gland and 1 into the right apex. All patients were treated to a dose of 78Gy in 39 fractions with IMRT.Daily orthogonal 2D EPIs were taken of each patient in treatment position prior to RT. Elekta I-View template matching software was used to analyse these images. Online pre-treatment verification was performed using the 3 seeds.In the offline setting, matches of dual seed combinations (base and mid gland, base and apex, mid gland and apex), individual seeds (base, mid gland, apex) and bony anatomy were performed for each fraction of all 10 patients.

RESULTS

The average correctional shifts (with ranges) for the different seed combinations in mm were:3 seed: Right-Left (RL) 0.9 (-4.6 to 6.5), Superior-Inferior (SI) -0.3 (-9.8 to 6.3), Anterior-Posterior (AP) -0.3 (-8.6 to 9.1).Base and mid gland: RL 0.9 (-6.1 to 6.5), SI -0.4 (-10.1 to 6.8), AP -0.2 (-8.3 to 9.6)Base and apex: RL 1.1 (-5.3 to 7.3), SI -0.4 (-9.4 to 6.1), AP -0.2 (-9.1 to 9.6)Mid gland and apex: RL 0.9 (-5.8 to 7.3), SI -0.2 (-9.8 to 6.6), AP -0.1 (-8.1 to 12)Base: RL 1.0 (-5.0 to 6.6), SI -0.6 (-10.1 to 7.3), AP -0.3 (-9.1 to 10.4)Mid gland: RL 0.7 (-6.8 to 6.5), SI -0.2 (-10.1 to 6.8), AP -0.2 (-8.6 to 8.9)Apex: RL 1.1 (-4.8 to 6.8), SI -0.1 (-10.1 to 6.6), AP -0.1 (-8.3 to 9.6)Bone: RL 0.9 (-6.8 to 7.0), SI -1.0 (-9.4 to 5.3), AP 0.7 (-13.8 to 8.3)

CONCLUSION

The study shows that the matching of 1 or 2 gold prostate seeds closely approximates that of 3 seeds. The difference between the 2 seed combinations- notably the base and mid gland- is less than 1mm. The study also illustrates that a 1 seed match more closely approximates the standard 3 seed match than bony verification.The reduction in the number of seeds inserted into the prostate has a number of advantages, including minimisation of morbidity associated with insertion, decrease in insertion time and a reduction in cost.

Cite This Abstract

Lim Joon, D, Khoo, V, Mercuri, A, Rolfo, A, Wan, K, Gonzales, S, Stewart, R, Spiteri, L, Handley, M, Benci, M, Daly, K, Hamilton, C, et al, , Prostate Radiotherapy: Is One or Two Gold Seeds Equivalent to Three?.  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/7000407.html